Generex receives price approval for Oral-lyn
Generex Biotechnology Corporation has been granted price approval by the US Food and Drug Administration approval for the use of Generex Oral-lyn(TM) under the FDA’s Treatment Investigational New Drug (IND) program. Generex was previously granted the FDA approval for the use of Generex Oral-lyn(TM) in patients with Type 1 or Type 2 diabetes mellitus under the FDA’s “Treatment IND” rules.
- Generex Oral-lyn Phase III patient screening starts
- Mylan receives approval for generic Cytomel
- FDA approves Duramed’s LoSEASONIQUE(R) oral contraceptive
- CSL Behring Receives FDA Approval of Berinert(R)
